Trulieve announces production license approval in Georgia, expands southeast hub
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, today announced that the Georgia Access to Medical Cannabis Commission announced its intent to award Trulieve a Class 1 production license. This license will further solidify Trulieve’s presence in the Southeastern United States and introduce its premium products in Georgia’s nascent medical cannabis market.
“We are thrilled by the Georgia Access to Medical Cannabis Commission announcement of its intent to award Trulieve one of two Class 1 production licenses in the State of Georgia. This will expand our Southeast operations hub to our neighboring state, and we are excited to bring the benefits of Trulieve cannabis products to Georgia patients,” said Kim Rivers, CEO of Trulieve. “As the largest cannabis company in Florida, built on providing the broadest patient access to medical marijuana in the state, we feel well-positioned to approach the Georgia market with the same commitment to quality products, patient access, and positive customer experience. We strive to invest in underserved communities, source local materials and labor wherever possible, and be a good neighbor and partner everywhere we operate, and this is what we intend to bring to the town of Adel and to Cook County. We thank all of the people and organizations that contributed to our success in this highly competitive process and will work to rapidly establish Georgia operations to ensure this life-changing alternative is quickly accessible for those who need it most.”
Trulieve is one of two Class 1 provisional licensees in Georgia and will initially establish an indoor cultivation and manufacturing facility in Adel to produce low-THC oil products. Trulieve is committed to investing in the communities in which it operates and will further this commitment by working with well-regarded local businesses during construction and throughout operation. The resulting operation and its ancillary business partners are projected to generate hundreds of jobs for Cook County, Georgia and the surrounding area within a matter of years. Trulieve will also further medical cannabis research and education through a previously announced partnership with Morehouse School of Medicine in Atlanta.
About Trulieve
Trulieve is primarily a vertically integrated “seed-to-sale” company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve is also a licensed operator in California, Massachusetts, Connecticut, Pennsylvania, and West Virginia. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.
To learn more about Trulieve, visit www.Trulieve.com.
The Canadian Securities Exchange has not reviewed, approved, or disapproved the content of this news release.
Forward-Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company and statements with regard to the Report and the Company’s response thereto. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risks discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and in subsequent periodic and current reports filed with the United States Securities and Exchange Commission and in the Company’s filings on SEDAR at www.sedar.com Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
